Limits...
Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction.

Shojaie M, Sotoodah A, Roozmeh S, Kholoosi E, Dana S - Thromb J (2009)

Bottom Line: Annexin V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent anticoagulant effect in vitro by reducing plaque adhesion and aggregation.Plasma levels of ANV, aANVAs and aCLAs were determined by enzyme-linked immunosorbent assay and the results were compared.Positive test for aANVAs were found to be present in a significant number of our patients (p = 0.004).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Cardiology, Jahrom University of Medical science, Jahrom, Iran. shojaie1300@yahoo.com.

ABSTRACT

Background: Myocardial infarction is the combined result of environmental factors and personal predispositions. Prothrombotic factors might play an important role in this phenomenon. Annexin V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent anticoagulant effect in vitro by reducing plaque adhesion and aggregation. Anti-annexin V antibodies (aANVAs) are detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of ANV in Acute Myocardial Infarction (AMI) might shed light on hypercoagulability mechanisms in the pathogenesis of acute coronary syndromes. This study was conducted to investigate the association of plasma ANV, aANVAs and anti-cardiolipin antibodies (aCLAs) with AMI.

Methods: This study recruited 45 patients with the diagnosis of AMI according to WHO criteria in their first 24 hours of admission. 36 matched individuals were studied as the control group with normal coronary artery angiography. Plasma levels of ANV, aANVAs and aCLAs were determined by enzyme-linked immunosorbent assay and the results were compared.

Results: Plasma ANV levels in the patients with AMI on admission were significantly lower than those in the control group (p = 0.002). Positive test for aANVAs were found to be present in a significant number of our patients (p = 0.004). The studied groups were similar in their rate of patients with positive aCLAs tests. ANV, aANVAs and aCLAs were not correlated with hypertension, diabetes mellitus, hyperlipidemia, sex, age and smoking.

Conclusion: Our findings suggest that low plasma ANV levels along with positive aANVAs tests in patients with AMI are indicative of hypercoagulable state that is not related to the traditional cardiovascular risk factors.

No MeSH data available.


Related in: MedlinePlus

Positive anti-ANV antibodies in patients who had an acute myocardial infarction and in controls, 20(45.5%) vs. 6(15.8%), p = 0.004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2724414&req=5

Figure 2: Positive anti-ANV antibodies in patients who had an acute myocardial infarction and in controls, 20(45.5%) vs. 6(15.8%), p = 0.004.

Mentions: The demographic and clinical characteristics of the study groups, as well as laboratory variables are shown in Table 1. In patient group 6 cases (14%) had non-ST elevation MI (NSTEMI) and 37 (86%) had ST elevation MI (STEMI). There was no significant difference between the two groups regarding the following variables: age, sex, presence of HTN, DM, LDL, HDL, total cholesterol and TG. Plasma ANV levels in patients with AMI on admission were significantly lower than those in the control group (0.83 ± 0.77 ng/ml vs. 4.12 ± 2.88 ng/ml, p = 0.002) (Fig 1). Also, our patients had significantly more positive anti-annexin V antibody results than the control group [20(45.5%) vs. 6(15.8%), p = 0.004] (Fig 2) but no difference was found in the aCLAs test results between the two groups (Table 1).


Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction.

Shojaie M, Sotoodah A, Roozmeh S, Kholoosi E, Dana S - Thromb J (2009)

Positive anti-ANV antibodies in patients who had an acute myocardial infarction and in controls, 20(45.5%) vs. 6(15.8%), p = 0.004.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2724414&req=5

Figure 2: Positive anti-ANV antibodies in patients who had an acute myocardial infarction and in controls, 20(45.5%) vs. 6(15.8%), p = 0.004.
Mentions: The demographic and clinical characteristics of the study groups, as well as laboratory variables are shown in Table 1. In patient group 6 cases (14%) had non-ST elevation MI (NSTEMI) and 37 (86%) had ST elevation MI (STEMI). There was no significant difference between the two groups regarding the following variables: age, sex, presence of HTN, DM, LDL, HDL, total cholesterol and TG. Plasma ANV levels in patients with AMI on admission were significantly lower than those in the control group (0.83 ± 0.77 ng/ml vs. 4.12 ± 2.88 ng/ml, p = 0.002) (Fig 1). Also, our patients had significantly more positive anti-annexin V antibody results than the control group [20(45.5%) vs. 6(15.8%), p = 0.004] (Fig 2) but no difference was found in the aCLAs test results between the two groups (Table 1).

Bottom Line: Annexin V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent anticoagulant effect in vitro by reducing plaque adhesion and aggregation.Plasma levels of ANV, aANVAs and aCLAs were determined by enzyme-linked immunosorbent assay and the results were compared.Positive test for aANVAs were found to be present in a significant number of our patients (p = 0.004).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Cardiology, Jahrom University of Medical science, Jahrom, Iran. shojaie1300@yahoo.com.

ABSTRACT

Background: Myocardial infarction is the combined result of environmental factors and personal predispositions. Prothrombotic factors might play an important role in this phenomenon. Annexin V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent anticoagulant effect in vitro by reducing plaque adhesion and aggregation. Anti-annexin V antibodies (aANVAs) are detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of ANV in Acute Myocardial Infarction (AMI) might shed light on hypercoagulability mechanisms in the pathogenesis of acute coronary syndromes. This study was conducted to investigate the association of plasma ANV, aANVAs and anti-cardiolipin antibodies (aCLAs) with AMI.

Methods: This study recruited 45 patients with the diagnosis of AMI according to WHO criteria in their first 24 hours of admission. 36 matched individuals were studied as the control group with normal coronary artery angiography. Plasma levels of ANV, aANVAs and aCLAs were determined by enzyme-linked immunosorbent assay and the results were compared.

Results: Plasma ANV levels in the patients with AMI on admission were significantly lower than those in the control group (p = 0.002). Positive test for aANVAs were found to be present in a significant number of our patients (p = 0.004). The studied groups were similar in their rate of patients with positive aCLAs tests. ANV, aANVAs and aCLAs were not correlated with hypertension, diabetes mellitus, hyperlipidemia, sex, age and smoking.

Conclusion: Our findings suggest that low plasma ANV levels along with positive aANVAs tests in patients with AMI are indicative of hypercoagulable state that is not related to the traditional cardiovascular risk factors.

No MeSH data available.


Related in: MedlinePlus